Paul Hastings
2016 - OncoMed Pharmaceuticals
In 2016, Paul Hastings earned a total compensation of $958.7K as Chairman, Chief Executive Officer & President at OncoMed Pharmaceuticals, a 69% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $264,862 |
|---|---|
| Salary | $535,075 |
| Stock Awards | $158,760 |
| Total | $958,697 |
Hastings received $535.1K in salary, accounting for 56% of the total pay in 2016.
Hastings also received $264.9K in non-equity incentive plan and $158.8K in stock awards.
Rankings
In 2016, Paul Hastings' compensation ranked 8,439th out of 14,075 executives tracked by ExecPay. In other words, Hastings earned more than 40.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,439 out of 14,075 | 40th |
Division Manufacturing | 3,235 out of 5,486 | 41st |
Major group Chemicals And Allied Products | 1,090 out of 1,900 | 43rd |
Industry group Drugs | 851 out of 1,543 | 45th |
Industry Pharmaceutical Preparations | 674 out of 1,173 | 43rd |
Source: SEC filing on April 13, 2017.
Hastings' colleagues
We found two more compensation records of executives who worked with Paul Hastings at OncoMed Pharmaceuticals in 2016.